Streetbeat News

Regulatory

HYMTF

Hyundai Motor is recalling approximately 145,235 electrified vehicles in the US due to a loss of drive power, as reported by the National Highway Traffic Safety Administration.

Portfolio Pulse from

November 22, 2024 | 11:00 am

BNDSF

Spain's Sabadell will allocate tens of millions of euros in provisions to address the impact of recent floods in eastern Spain. The bank considers the impact manageable.

Portfolio Pulse from

November 22, 2024 | 10:30 am

VTRS

The UK's competition watchdog has fined Viatris $1.9 million for breaching rules during an investigation into Theramex's acquisition of European rights to two of Viatris's women's healthcare product ranges.

Portfolio Pulse from

November 22, 2024 | 10:15 am

IVBXF

The Claudin18.2-targeted therapy market is projected to grow due to positive results from current medications and an expanding pipeline. The market is characterized by global collaboration and competition, with significant contributions from both Western and Asian companies. This growth is expected to enhance cancer treatment options, particularly for difficult-to-treat cancers.

Portfolio Pulse from

November 22, 2024 | 10:00 am

GSK

GSK's RSV vaccine, Arexvy, has been approved by Japan's Ministry of Health for use in adults aged 50-59 at increased risk of severe RSV-related outcomes. This expands its previous approval for those aged 60 and older.

Portfolio Pulse from

November 22, 2024 | 9:15 am

UNH

UnitedHealth Group has underperformed in 2024 but shows potential for growth in 2025. Despite regulatory uncertainties, UNH delivered strong Q3 results with EPS of $7.15 and revenue of $101 billion. The stock is slightly undervalued with a target price near $618.

Portfolio Pulse from

November 22, 2024 | 8:15 am

GSK

GSK's RSV vaccine has been approved in Japan for expanded use in adults aged 50 to 59, who are at increased risk of severe RSV disease.

Portfolio Pulse from

November 22, 2024 | 8:00 am

HOPHF

Hemogenyx Pharmaceuticals has received IRB approval to start a Phase I clinical trial for its lead therapy, HEMO-CAR-T, targeting relapsed/refractory acute myeloid leukemia.

Portfolio Pulse from

November 22, 2024 | 8:00 am

AAPL

Apple's proposal to invest $100 million in Indonesia is under scrutiny as the iPhone 16 does not meet the country's 40% domestic content requirement. The Indonesian government is seeking a better offer from Apple to allow the sale of the iPhone 16 in the country.

Portfolio Pulse from

November 22, 2024 | 7:00 am